Effect of Intravesical Instillation Therapy on Cancer-specific Survival Rate of Stage T1 Non-muscle-invasive Bladder Transitional Cell Carcinoma Patients After Transurethral Resection
10.3971/j.issn.1000-8578.2022.22.0297
- VernacularTitle:膀胱灌注治疗对T1期非肌层浸润性膀胱移行细胞癌患者经尿道膀胱肿瘤切除术后癌症特异性生存率的影响
- Author:
Lan MA
1
;
Ruchun YANG
Author Information
1. Department of Nephropathy, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310007, China
- Publication Type:Research Article
- Keywords:
Intravesical instillation therapy;
T1 stage;
Bladder cancer;
Transurethral resection of bladder tumor;
Propensity score matching
- From:
Cancer Research on Prevention and Treatment
2022;49(12):1269-1275
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of transurethral resection of bladder tumor (TURBT) with or without intravesical instillation therapy on cancer-specific-survival rate (CSS) of T1 stage non-muscle-invasive bladder transitional cell carcinoma (BTCC) patients. Methods The data of patients diagnosed with T1 stage non-muscle-invasive BTCC from 2010 to 2015 were obtained from the SEER database. The different dividing groups were based on TURBT with or without intravesical instillation therapy. A 1:1 PSM method was used to balance the differences in baseline data between each group. Herein, Kaplan-Meier methods were used to draw survival curves, and the difference between OS and CSS were compared by Log rank test. In addition, univariate and multivariate Cox regressionanalyses were used to explore the independent risk factors of CSS. Results The OS and CSS of patients in the TURBT combined with intravesical instillation therapy group were higher than those of the TURBT alone group (P < 0.05). TURBT combined with intravesical instillation therapy was a protective factor in prognosis with T1 stage non-muscle-invasive BTCC patients (HR=0.783, 95%CI: 0.650-0.942, P < 0.01). Conclusion TURBT combined with intravesical instillation therapy improves the CSS of patients with T1 stage non-muscle-invasive BTCC.
